Glucagon resistance in fatty liver and diabetes
Part of Hormones & metabolism clinical trials.
This study looks at how people with fatty liver and type 2 diabetes respond to glucagon, a hormone that helps control blood sugar. It may help researchers understand a condition called 'glucagon resistance' and find better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a body mass index (BMI) over 26.
- You have been diagnosed with type 2 diabetes for at least 6 months.
- You have a fatty liver (more than 5.6% fat on specialized scans).
- You do not smoke or drink heavily (more than 10 drinks per week).
- You are not pregnant, and you have no history of cancer, heart attack, or heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study looks at people with type 2 diabetes to learn more about fatty liver disease. By joining, you may help doctors better understand how these conditions are linked and improve future care.
This study looks at ways to better understand and treat fatty liver disease linked to obesity and metabolism problems. Researchers want to see what factors affect the condition and how to manage it.
This Phase 2 study tests how glucagon affects sugar and fat handling in the liver after a short period of calorie restriction. It may help researchers understand metabolic changes in people with type 2 diabetes and guide future treatments.
This study looks at how the liver handles insulin and glucagon, two hormones that control blood sugar. It is for healthy adults to help researchers understand normal liver function.
This study looks at how glucagon affects insulin release and blood sugar in people who do not have type 2 diabetes. It may help us understand normal glucose control better.
This study tests whether very low-carbohydrate diets change glucagon response in adults with type 1 diabetes. It may help researchers understand how diet affects blood-sugar control in people using insulin pumps and continuous glucose monitors.
Hear when a new Metabolic Associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.